Ignite Creation Date:
2025-12-24 @ 10:35 PM
Ignite Modification Date:
2025-12-31 @ 4:22 PM
Study NCT ID:
NCT05627635
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-07
First Post:
2022-11-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
Sponsor:
City of Hope Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-05-03
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06-23
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-06-23
Completion Date Type:
ESTIMATED
First Submit Date:
2022-11-17
First Submit QC Date:
None
Study First Post Date:
2022-11-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-06
Last Update Post Date:
2025-11-07
Last Update Post Date Type:
ESTIMATED